top of page


Treatment of Parkinson’s-related Depression

Company Name
Updating Date
Neurotech Category
Market Category
Target Market
Company Founded Year
Company Number of Employees
Biotechnology & Biopharmaceutical
Go to company site

N2B Ltd is developing an intranasal delivery formulation of the approved drug Rasagiline for the treatment of depression associated with Parkinson’s disease (PD). The company is on a quick regulatory pathway for NDA submission through the U.S. FDA 5O5(b)(2) approach.

N2B’s preclinical results indicate that intranasal delivery of Rasagiline could provide both a useful alternative to oral administration in the treatment of PD and a novel therapeutic approach for the treatment of depression in PD patients.

N2B was founded as an incubator company of Youdim Pharmaceuticals.

bottom of page